OBJECTIVE: Describe the consequences of dextropropoxyphene (DXP) market withdrawal on analgesic prescriptions and on the quality of therapeutic management of chronic pain. PATIENTS AND METHODS: From a cohort of non-institutionalised elderly patients with chronic pain recruited by general practitioners, we selected patients who were treated with DXP daily for at least 6 months just prior to DXP market withdrawal and who had an evaluation of pain and its impact on daily activities before and after DXP withdrawal. RESULTS: One hundred three patients took DXP daily for chronic pain. Immediately after DXP market withdrawal, 42 (40.8%), 55 (53.4%) and 3 (2.9%) patients were treated with step 1, 2 and 3 analgesics, respectively, and 3 patients (2.9%) were no longer receiving any analgesic medication. Among the 55 patients who continued on step 2 analgesics, 37 were treated with tramadol, 14 with codeine and 9 with opium. Pain intensity and the impact of pain on daily activities remained stable. CONCLUSION: DXP market withdrawal had no consequences on the intensity or impact of chronic pain in elderly patients.
OBJECTIVE: Describe the consequences of dextropropoxyphene (DXP) market withdrawal on analgesic prescriptions and on the quality of therapeutic management of chronic pain. PATIENTS AND METHODS: From a cohort of non-institutionalised elderly patients with chronic pain recruited by general practitioners, we selected patients who were treated with DXP daily for at least 6 months just prior to DXP market withdrawal and who had an evaluation of pain and its impact on daily activities before and after DXP withdrawal. RESULTS: One hundred three patients took DXP daily for chronic pain. Immediately after DXP market withdrawal, 42 (40.8%), 55 (53.4%) and 3 (2.9%) patients were treated with step 1, 2 and 3 analgesics, respectively, and 3 patients (2.9%) were no longer receiving any analgesic medication. Among the 55 patients who continued on step 2 analgesics, 37 were treated with tramadol, 14 with codeine and 9 with opium. Pain intensity and the impact of pain on daily activities remained stable. CONCLUSION:DXP market withdrawal had no consequences on the intensity or impact of chronic pain in elderly patients.
Authors: P Bertin; L Becquemont; E Corruble; G Derumeaux; B Falissard; O Hanon; M Pinget; F Forette Journal: J Nutr Health Aging Date: 2013 Impact factor: 4.075
Authors: Cécile Pageot; Julien Bezin; Andy Smith; Mickael Arnaud; Francesco Salvo; Françoise Haramburu; Bernard Bégaud; Antoine Pariente Journal: Drug Saf Date: 2017-11 Impact factor: 5.606
Authors: Corey J Hayes; Teresa J Hudson; Martha M Phillips; Zoran Bursac; James S Williams; Mark A Austin; Mark J Edlund; Bradley C Martin Journal: Pharmacoepidemiol Drug Saf Date: 2015-08-06 Impact factor: 2.890
Authors: E Van Ganse; M Belhassen; M Ginoux; E Chrétien; C Cornu; C Ecoffey; F Aubrun Journal: BMC Health Serv Res Date: 2018-04-02 Impact factor: 2.655